MENU
+Compare
ELDN
Stock ticker: NASDAQ
AS OF
May 21, 04:59 PM (EDT)
Price
$3.14
Change
+$0.08 (+2.61%)
Capitalization
183.24M

ELDN stock forecast, quote, news & analysis

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company... Show more

ELDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for ELDN with price predictions
May 20, 2025

ELDN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ELDN turned positive on May 20, 2025. Looking at past instances where ELDN's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Momentum Indicator moved above the 0 level on May 20, 2025. You may want to consider a long position or call options on ELDN as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ELDN advanced for three days, in of 245 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 50-day moving average for ELDN moved below the 200-day moving average on April 28, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELDN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ELDN broke above its upper Bollinger Band on April 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ELDN entered a downward trend on April 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.599) is normal, around the industry mean (16.516). P/E Ratio (4.808) is within average values for comparable stocks, (60.627). ELDN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.210). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (283.856).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ELDN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELDN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.2B. The market cap for tickers in the group ranges from 151 to 305.18B. NONOF holds the highest valuation in this group at 305.18B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 6%. For the same Industry, the average monthly price growth was 10%, and the average quarterly price growth was -1%. CVM experienced the highest price growth at 1,770%, while URGN experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -5%. For the same stocks of the Industry, the average monthly volume growth was 80% and the average quarterly volume growth was 87%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 62
SMR Rating: 90
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
ELDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
19900 MacArthur Boulevard
Phone
+1 949 238-8090
Employees
20
Web
https://www.eledon.com